Image

STrategies for Catheter Ablation of peRsistent Atrial Fibrlllation

Recruiting
18 years of age
Both
Phase N/A

Powered by AI

Overview

The objective of this study is to compare the efficacy of three different ablation strategies in patients with persistent AF:

  1. PV antral isolation alone (PVAI)
  2. PV antral isolation plus ablation of drivers (PVAI+drivers)
  3. PV antral isolation plus isolation of posterior wall (PVAI+box) All three strategies will employ contemporary catheter ablation technology using more efficient open irrigated tip cooling and contact force sensing.

Eligibility

Inclusion Criteria:

  1. Patients 18 years of age or older
  2. Patients undergoing first-time ablation procedure for AF
  3. Patients with persistent AF defined as a sustained episode more than 3 months but less than three years
  4. Patients with symptomatic AF - symptomatic patients are those who have been aware of their AF at any time within the last 5 years prior to enrolment. Symptoms may include, but are not restricted to, palpitations, shortness of breath, chest pain, fatigue, left ventricular dysfunction, or other symptoms or any combination of the above
  5. Patients whose AF has been refractory to at least one antiarrhythmic drug
  6. At least one episode of AF must have been documented by ECG, holter, loop recorder, telemetry, trans-telephonic monitor or implanted device within the last 2 years from enrolment
  7. Patients must be able and willing to provide written informed consent to participate in the study

Exclusion Criteria:

  1. Patients with paroxysmal AF (no episodes lasting > 7 days)
  2. Patients with early persistent AF, sustained episode ≤ 3 months
  3. Patients with very long lasting persistent AF (episodes lasting > 3 years)
  4. Patients with CHA2DS2-VASc score of 0.
  5. Patients for whom cardioversion or sinus rhythm will never be attempted/pursued
  6. Patients with AF felt to be secondary to an obvious reversible cause
  7. Patients with contraindication to oral anticoagulation or systemic anticoagulation with heparin
  8. Patients with left atrial diameter > 60 mm in the parasternal long axis view
  9. Patients who are pregnant

Study details

Atrial Fibrillation

NCT04428944

McGill University Health Centre/Research Institute of the McGill University Health Centre

23 June 2024

Step 1 Get in touch with the nearest study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.